A double-blind trial of disodium cromoglycate in the treatment of allergic bronchial asthma

Abstract A double-blind cross-over sequential trial of a new antiallergic compound, disodium cromoglycate (' FPL670 ', ' Intal ') was carried out over a period of 6 weeks in ten patients severely disabled with allergic bronchial asthma. There was a significant clinical improvement during administration of FPL670 plus isoprenaline in all patients compared with two periods in which isoprenaline alone was given. Spirometric improvement occurred in only four patients. Subsequent experience over periods up to 26 months with these and other patients has confirmed the therapeutic value and safety of FPL670 in the management of allergic bronchial asthma.